🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06681155
Starting soon Observational

Identification Of High-risk Coronary Plaques By Multimodal Intravascular Imaging

NCT06681155 · tracked via the Priya Life Science China tracker
Sponsor
Chinese PLA General Hospital
Phase
Observational
Started
2024-11
Last updated
2024-11-08

Condition(s) studied

Coronary Arterial Disease (CAD)Acute Coronary Syndromes

Investigational drug(s) / intervention(s)

Assessment of plaque morphology, structure, and stability in non-culprit lesions

Assessment of plaque morphology, structure, and stability in non-culprit lesions: Assessment of plaque morphology, structure, and stability in non-culprit lesions based on intravascular ultrasound and optical coherence tomography-near-infrared spectroscopy imaging technology.

Study summary

This study is a multicenter prospective observational clinical study, which will be conducted in 11 hospitals, and approximately 500 subjects will be enrolled. Plaque morphology and stability of non-culprit lesions were assessed by intravascular ultrasound (IVUS) and optical coherence tomography-near-infrared spectroscopy (OCT) after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS). Plaques were grouped according to high-risk or non-high-risk. Clinical follow-up was conducted after PCI.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Inclusion criteria for the clinical study: 1. Aged ≥18 years at enrollment, male or female; 2. Meets the diagnosis of acute coronary syndrome, including acute myocardial infarction and unstable angina. Acute myocardial infarction includes ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (non-STEMI). STEMI is defined as chest pain lasting at least 30 minutes, arriving at the hospital within 12 hours from the onset of symptoms, changes in the 12-lead ECG (ST-segment elevation \>0.1 mV in ≥2 consecutive leads or new left bundle branch block), and elevated cardiac biomarkers (troponin T/I). Non-STEMI is defined as ischemic symptoms without ST-segment elevation on ECG, accompanied by elevated cardiac biomarkers. Unstable angina is defined as chest pain lasting 5-30 minutes at rest, or worsening of exertional angina, and accompanied by one of the following: transient ST-segment depression or elevation; coronary angiography showing luminal narrowing ≥90% or plaque rupture or thrombotic lesions. 3. Planned to undergo coronary angiography and PCI treatment; 4. Hemodynamically stable and able to tolerate repeated intracoronary administration of nitroglycerin; 5. Capable of understanding the requirements of this study, willing to participate in the study, and have signed an informed consent form. * Imaging inclusion criteria: 1. Coronary angiography clearly shows that the patient has at least one non-culprit lesion with a visual assessment of diameter stenosis between 40-70%, and the operator believes that interventional treatment intervention is not temporarily necessary; 2. The site of the non-culprit lesion has not previously had a stent implanted. Exclusion Criteria: * Exclusion criteria for the clinical study: 1. Cardiogenic shock or hemodynamic instability; 2. History of coronary artery bypass grafting (CABG), or planned CABG; 3. Severe renal impairment (glomerular filtration rate \<30ml/min/1.73m²); 4. Life expectancy of less than 2 years; 5. Currently participating in other ongoing investigative device or drug studies that have not yet reached their primary endpoints. * Imaging exclusion criteria: The anatomical structure of the non-culprit lesion is not suitable for intravascular imaging catheter imaging (lesions at the left main trunk or right coronary artery ostium, severe calcification, chronic total occlusion, etc.).

Primary outcome measure(s)

Trial sites (11)

FacilityCityRegionStatus
Shenzhen People's Hospital Shenzhen Guandong
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei
Wuhan Asian Heart Hospital Wuhan Hubei
China-Japan Union Hospital of Jilin University Changchun Jilin
Xi'an Jiaotong University Second Affiliated Hospital Xi'an Shaanxi
People's Hospital of Xinjiang Uygur Autonomous Region Ürümqi Xinjiang Uygur Autonomous Region
The Second Affiliated Hospital, Zhejiang University Hangzhou Zhejiang
Beijing Anzhen Hospital, Capital Medical University Beijing China
Beijing Jishuitan Hospital Beijing China
Fuwai Hospital, Chinese Academy of Medical Sciences Beijing China
People's Liberation Army General Hospital Beijing China

More Chinese PLA General Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06681155 on ClinicalTrials.gov ↗ ← All trials in China